Denali Therapeutics (NASDAQ:DNLI) Releases Quarterly Earnings Results, Misses Estimates By $0.03 EPS

Denali Therapeutics (NASDAQ:DNLI) released its earnings results on Wednesday. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.03), Briefing.com reports. During the same quarter in the prior year, the company earned ($0.72) earnings per share.

Denali Therapeutics Price Performance

DNLI stock traded up $0.15 during midday trading on Thursday, hitting $29.70. 625,006 shares of the stock traded hands, compared to its average volume of 1,071,400. The firm has a market cap of $4.25 billion, a P/E ratio of -10.37 and a beta of 1.40. The stock’s fifty day simple moving average is $27.57 and its 200-day simple moving average is $23.36. Denali Therapeutics has a 1-year low of $14.56 and a 1-year high of $32.13.

Analysts Set New Price Targets

Several equities research analysts have issued reports on DNLI shares. Jefferies Financial Group increased their target price on Denali Therapeutics from $40.00 to $45.00 and gave the stock a “buy” rating in a research report on Friday, November 1st. Raymond James reiterated a “market perform” rating on shares of Denali Therapeutics in a research report on Thursday, October 10th. Wedbush lowered their price target on Denali Therapeutics from $30.00 to $26.00 and set an “outperform” rating on the stock in a research report on Friday, August 2nd. HC Wainwright restated a “buy” rating and set a $90.00 price target on shares of Denali Therapeutics in a research report on Thursday. Finally, Cantor Fitzgerald downgraded Denali Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Monday, October 7th. Three analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Denali Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $38.90.

Insider Activity

In other news, Director Steve E. Krognes sold 30,000 shares of Denali Therapeutics stock in a transaction dated Monday, September 30th. The shares were sold at an average price of $29.03, for a total value of $870,900.00. Following the sale, the director now owns 29,096 shares in the company, valued at $844,656.88. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other Denali Therapeutics news, CEO Ryan J. Watts sold 40,000 shares of Denali Therapeutics stock in a transaction dated Friday, October 18th. The shares were sold at an average price of $27.69, for a total transaction of $1,107,600.00. Following the transaction, the chief executive officer now directly owns 235,807 shares of the company’s stock, valued at $6,529,495.83. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Steve E. Krognes sold 30,000 shares of Denali Therapeutics stock in a transaction dated Monday, September 30th. The stock was sold at an average price of $29.03, for a total transaction of $870,900.00. Following the transaction, the director now directly owns 29,096 shares in the company, valued at $844,656.88. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 7.90% of the company’s stock.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.